These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933 [TBL] [Abstract][Full Text] [Related]
5. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma]. Iakovleva SV; Andreeva NE; Izgorodin AS Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303 [TBL] [Abstract][Full Text] [Related]
6. Plasma cell leukemia 3 months after autologous blood cell transplantation for multiple myeloma. Koskela K; Pelliniemi TT; Lakkala T; Remes K Bone Marrow Transplant; 1998 Feb; 21(3):305-7. PubMed ID: 9489657 [TBL] [Abstract][Full Text] [Related]
7. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713 [TBL] [Abstract][Full Text] [Related]
9. Plasma cell leukemia: from biology to treatment. Jelinek T; Kryukov F; Rihova L; Hajek R Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252 [TBL] [Abstract][Full Text] [Related]
11. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Dimopoulos MA; Barlogie B; Smith TL; Alexanian R Ann Intern Med; 1991 Dec; 115(12):931-5. PubMed ID: 1952489 [TBL] [Abstract][Full Text] [Related]
12. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277 [TBL] [Abstract][Full Text] [Related]
13. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation]. Telek B; Méhes L; Batár P; Kiss A; Udvardy M Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514 [TBL] [Abstract][Full Text] [Related]
14. Acute leukemia of plasmablastic type as terminal phase of multiple myeloma. Piccinini L; Artusi T; Bonacorsi G; Arigliano V Haematologica; 2002 Feb; 87(2):EIM04. PubMed ID: 11836178 [No Abstract] [Full Text] [Related]
18. [Plasma cell leukemia. Study of 6 patients]. Las Heras G; Ribera JM; Abella E; Batlle M; Flores A; Millá F; Feliu E Sangre (Barc); 1992 Aug; 37(4):255-8. PubMed ID: 1514138 [TBL] [Abstract][Full Text] [Related]
19. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504 [TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]